Journal
LEUKEMIA
Volume 24, Issue 4, Pages 748-755Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2009.296
Keywords
myelodysplastic syndrome; lenalidomide; cytokinesis; del(5q)
Categories
Funding
- Celgene K.K.
- Japanese Cooperative Study Group for Intractable Bone Marrow Diseases, Ministry of Health, Labor and Welfare of Japan
- Japan Society for the Promotion of Science
- Kawasaki Medical School
Ask authors/readers for more resources
Myelodysplastic syndromes (MDS) are a group of hematopoietic stem cell disorders characterized by refractory cytopenias and susceptibility to leukemic transformation. On a subset of MDS patients with deletion of the long arm of chromosome5 (del(5q)), lenalidomide exerts hematological and cytogenetic effects, but the underlying pharmacological mechanisms are not fully understood. In this study, we have investigated the in vitro effects of lenalidomide on an MDS-derived cell line, MDS-L, which carries del(5q) and complex chromosome abnormalities. We found that the growth of MDS-L cells was specifically suppressed mainly by apoptosis, and in addition, multinucleated cells were frequently formed and finally died out in the presence of lenalidomide. Time-lapse microscopic observation and the DNA ploidy analysis revealed that lenalidomide does not affect DNA synthesis but inhibits cytokinesis of MDS-L cells. The gene expression profile showed decreased expression of M phase-related genes such as non-muscle myosin heavy-chain 10, polo-like kinase 1, aurora kinase B, citron kinase and kinesin family member 20A(KIF20A). Interestingly, KIF20A is located at 5q31. These data contribute to the understanding of action mechanisms of lenalidomide on MDS with del(5q) and complex abnormalities. Leukemia (2010) 24, 748-755; doi: 10.1038/leu.2009.296; published online 4 February 2010
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available